Literature DB >> 24879495

Acute subjective effects after smoking joints containing up to 69 mg Δ9-tetrahydrocannabinol in recreational users: a randomized, crossover clinical trial.

Claudine C Hunault1, Koen B E Böcker, R K Stellato, J Leon Kenemans, Irma de Vries, Jan Meulenbelt.   

Abstract

RATIONALE: An increase in the potency of the cannabis cigarettes has been observed over the past three decades.
OBJECTIVES: In this study, we aimed to establish the impact of Δ9-tetrahydrocannabinol (THC) on the rating of subjective effects (intensity and duration of the effects), up to 23 % THC potency (69 mg THC) among recreational users.
METHODS: Recreational users (N = 24) smoked cannabis cigarettes with four doses of THC (placebo 29, 49 and 69 mg of THC) on four separate test days in a randomized, double-blind, placebo-controlled, crossover study. The participants filled in three different questionnaires measuring subjective effects during the exposure up to 8 h post-smoking. The 'high' feeling, heart rate, blood pressure and THC serum concentrations were also regularly recorded during these 8 h.
RESULTS: THC significantly increased the high feeling, dizziness, dry-mouthed feeling, palpitations, impaired memory and concentration, and 'down', 'sedated' and 'anxious' feelings. In addition, THC significantly decreased alertness, contentment and calmness. A cubic relationship was observed between 'feeling the drug' and 'wanting more'. The THC-induced decrease in 'feeling stimulated' and increase in anxiety lasted up to 8 h post-smoking. Sedation at 8 h post-smoking was increased by a factor of 5.7 with the highest THC dose, compared to the placebo.
CONCLUSIONS: This study shows a strong effect of cannabis containing high percentages of THC on the rating of subjective effects. Regular users and forensic toxicologists should be aware that the THC-induced increase in 'feeling sedated' continues longer with a 69 mg THC dose than with a 29 mg THC dose.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24879495     DOI: 10.1007/s00213-014-3630-2

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  32 in total

1.  Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine.

Authors:  Emmanuel Valjent; Jennifer M Mitchell; Marie-Jo Besson; Jocelyne Caboche; Rafael Maldonado
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

Review 2.  Psychiatric effects of cannabis.

Authors:  A Johns
Journal:  Br J Psychiatry       Date:  2001-02       Impact factor: 9.319

Review 3.  Pharmacology and effects of cannabis: a brief review.

Authors:  C H Ashton
Journal:  Br J Psychiatry       Date:  2001-02       Impact factor: 9.319

4.  Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism.

Authors:  G Tanda; F E Pontieri; G Di Chiara
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

5.  Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users.

Authors:  H Valerie Curran; Catherine Brignell; Sally Fletcher; Paul Middleton; John Henry
Journal:  Psychopharmacology (Berl)       Date:  2002-07-23       Impact factor: 4.530

6.  Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC).

Authors:  Claudine C Hunault; Tjeert T Mensinga; Koen B E Böcker; C Maarten A Schipper; Maaike Kruidenier; Marianne E C Leenders; Irma de Vries; Jan Meulenbelt
Journal:  Psychopharmacology (Berl)       Date:  2008-12-20       Impact factor: 4.530

7.  Comparison of the subjective effects of Delta(9)-tetrahydrocannabinol and marijuana in humans.

Authors:  S R Wachtel; M A ElSohly; S A Ross; J Ambre; H de Wit
Journal:  Psychopharmacology (Berl)       Date:  2002-04-19       Impact factor: 4.530

8.  Simultaneous determination of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol and 11-nor-9-carboxy- Delta9-tetrahydrocannabinol in human plasma by high-performance liquid chromatography/tandem mass spectrometry.

Authors:  Barbora Maralikova; Wolfgang Weinmann
Journal:  J Mass Spectrom       Date:  2004-05       Impact factor: 1.982

9.  Effects of marijuana smoking on subjective ratings and tobacco smoking.

Authors:  R Nemeth-Coslett; J E Henningfield; M K O'Keeffe; R R Griffiths
Journal:  Pharmacol Biochem Behav       Date:  1986-09       Impact factor: 3.533

10.  Do Delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users?

Authors:  Erin L Karschner; Eugene W Schwilke; Ross H Lowe; W David Darwin; Harrison G Pope; Ronald Herning; Jean L Cadet; Marilyn A Huestis
Journal:  Addiction       Date:  2009-10-05       Impact factor: 6.526

View more
  29 in total

1.  Association of Naturalistic Administration of Cannabis Flower and Concentrates With Intoxication and Impairment.

Authors:  L Cinnamon Bidwell; Jarrod M Ellingson; Hollis C Karoly; Sophie L YorkWilliams; Leah N Hitchcock; Brian L Tracy; Jost Klawitter; Cristina Sempio; Angela D Bryan; Kent E Hutchison
Journal:  JAMA Psychiatry       Date:  2020-08-01       Impact factor: 21.596

2.  Does Marijuana Contribute to Intimate Partner Aggression? Temporal Effects in a Community Sample of Marijuana-Using Couples.

Authors:  Maria Testa; Jaye L Derrick; Weijun Wang; Kenneth E Leonard; Audrey Kubiak; Whitney C Brown; R Lorraine Collins
Journal:  J Stud Alcohol Drugs       Date:  2018-05       Impact factor: 2.582

3.  Temporal Changes in the Cross-Sectional Associations between Cannabis Use, Suicidal Ideation, and Depression in a Nationally Representative Sample of Canadian Adults in 2012 Compared to 2002.

Authors:  Jillian E Halladay; Catharine Munn; Michael Boyle; Susan M Jack; Katholiki Georgiades
Journal:  Can J Psychiatry       Date:  2019-06-09       Impact factor: 4.356

Review 4.  Cannabis-impaired driving and Canadian youth.

Authors:  Jeff R Brubacher; Herbert Chan; John A Staples
Journal:  Paediatr Child Health       Date:  2020-06-15       Impact factor: 2.253

Review 5.  The why behind the high: determinants of neurocognition during acute cannabis exposure.

Authors:  Johannes G Ramaekers; Natasha L Mason; Lilian Kloft; Eef L Theunissen
Journal:  Nat Rev Neurosci       Date:  2021-05-27       Impact factor: 34.870

Review 6.  Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations.

Authors:  Benedikt Fischer; Cayley Russell; Pamela Sabioni; Wim van den Brink; Bernard Le Foll; Wayne Hall; Jürgen Rehm; Robin Room
Journal:  Am J Public Health       Date:  2017-06-23       Impact factor: 9.308

Review 7.  Cannabis regulatory science: risk-benefit considerations for mental disorders.

Authors:  Jacob T Borodovsky; Alan J Budney
Journal:  Int Rev Psychiatry       Date:  2018-05-29

8.  Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of in vivo assays in mice.

Authors:  Jenny L Wiley; Timothy W Lefever; Julie A Marusich; Megan Grabenauer; Katherine N Moore; John W Huffman; Brian F Thomas
Journal:  Neuropharmacology       Date:  2016-07-20       Impact factor: 5.250

9.  Daily patterns of substance use and violence among a high-risk urban emerging adult sample: Results from the Flint Youth Injury Study.

Authors:  Patrick M Carter; James A Cranford; Anne Buu; Maureen A Walton; Marc A Zimmerman; Jason Goldstick; Quyen Ngo; Rebecca M Cunningham
Journal:  Addict Behav       Date:  2019-09-10       Impact factor: 3.913

10.  Controlled vaporized cannabis, with and without alcohol: subjective effects and oral fluid-blood cannabinoid relationships.

Authors:  Rebecca L Hartman; Timothy L Brown; Gary Milavetz; Andrew Spurgin; David A Gorelick; Gary Gaffney; Marilyn A Huestis
Journal:  Drug Test Anal       Date:  2015-08-10       Impact factor: 3.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.